Skip to content
  • BiotechReality JobFinder
  • Market Analysis
  • Publish on BiotechReality
  • linkedin
  • facebook
  • instagram
  • twitter
BiotechReality Home
BiotechReality – Information Intelligence System for Biopharma
  • Market Analysis
  • Healthcare & Pharmaceuticals
    • Business
    • Pharmacology
  • Clinical Trials
    • Regulatory Approval
  • Biotechnology
    • Molecular Biology
    • Genomics
    • Immunology
    • Microbiology
      • Virology
    • Diagnostic Tests
  • Science
    • Microbiology
    • Research
    • General Biology
  • Technology
    • Artificial Intelligence
  • News
    • Research
  • Newsletters
Popular
#FDA #Eli Lilly and Company #Johnson&Johnson #Clinical Data #Quarterly Results #FDA Approval #Phase 3 Trials #Novo Nordisk

Tag: Itvisma®

Regulatory Approval Healthcare & Pharmaceuticals Neuroscience News

Novartis Receives European Commission Approval for Itvisma for Spinal Muscular Atrophy

  • By Regulatory Intelligence Desk
  • 2 July 2026
novartis

Marking a major milestone, Novartis receives European Commission approval for Itvisma, introducing a fixed, one-time gene replacement therapy for a broad population of spinal muscular atrophy patients across Europe

Tagged European Commission, Itvisma®, Novartis, Spinal Muscular Atrophy
Advertisement

Areas Covered

  • Anti-obesity Drugs
  • Artificial Intelligence
  • Astrobiology
  • Autoimmune Diseases
  • Biochemistry
  • Bioengineering
  • Bioinformatics
  • Biologics
  • Biosimilars
  • Biostatistics
  • Biotechnology
  • Blog
  • Business
  • Cancer
  • CDMO
  • Cell Biology
  • Clinical Data
  • Clinical Investigation
  • Clinical Trials
  • Collection
  • CRDMO
  • CRO
  • Cybersecurity
  • Deep Learning
  • Diabetes
  • Diagnostic Tests
  • Disease Biology
  • Diseases
  • Drug Discovery
  • Drugs
  • Engineering
  • Epidemiology
  • Gene Therapy
  • General Biology
  • Genetics
  • Genomics
  • Healthcare & Pharmaceuticals
  • Immunology
  • Immunotherapy
  • Instrumentation
  • Laboratory Info
  • Legal and Patent Affairs
  • Life Sciences
  • Machine Learning
  • Manufacturing
  • Medical Devices
  • Mental Health
  • Merger & Acquisitions
  • Microbiology
  • Microscopy
  • Molecular Biology
  • Nanotechnology
  • Neuroscience
  • News
  • Oncology
  • Pharmacology
  • Rare Diseases
  • Regenerative Medicine
  • Regulatory
  • Regulatory Approval
  • Research
  • Science
  • Science Communication
  • Supply Chain
  • Technology
  • Therapies
  • Toxicology
  • Vaccines
  • Virology
  • Weight-loss Drugs

Discover More

Pfizer Starna Licensing Agreement: Pfizer Secures Exclusive In Vivo CAR-T Rights for Autoimmune Diseases in $330 Million Upfront Deal
Business Healthcare & Pharmaceuticals News

Pfizer Starna Licensing Agreement: Pfizer Secures Exclusive In Vivo CAR-T Rights for Autoimmune Diseases in $330 Million Upfront Deal

18 November 202618 November 2026
BiotechReality Business Intelligence Desk
Johnson & Johnson Announces $2.2 Billion Ollin Biosciences Acquisition to Add Phase 3 Eye Antibody OLN324
Business Clinical Trials Healthcare & Pharmaceuticals News

Johnson & Johnson Announces $2.2 Billion Ollin Biosciences Acquisition to Add Phase 3 Eye Antibody OLN324

17 November 202617 November 2026
BiotechReality Business Intelligence Desk
FDA Rejected Ivonescimab: Summit Therapeutics Receives Complete Response Letter for NSCLC BLA Based on HARMONi Study
Regulatory Healthcare & Pharmaceuticals News Oncology

FDA Rejected Ivonescimab: Summit Therapeutics Receives Complete Response Letter for NSCLC BLA Based on HARMONi Study

16 November 202616 November 2026
Clinical Trials & Data Desk
Novo Nordisk CagriSema REDEFINE 9 Trial Shows ~21% Average Weight Loss at Lower Doses at ObesityWeek 2026
Clinical Data Healthcare & Pharmaceuticals News

Novo Nordisk CagriSema REDEFINE 9 Trial Shows ~21% Average Weight Loss at Lower Doses at ObesityWeek 2026

15 November 202615 November 2026
Clinical Trials & Data Desk
Takeda ORZEYFUL Launch Brings First Orexin Agonist for Narcolepsy Type 1 to U.S. Patients
Healthcare & Pharmaceuticals Business News Rare Diseases

Takeda ORZEYFUL Launch Brings First Orexin Agonist for Narcolepsy Type 1 to U.S. Patients

14 November 202614 November 2026
BiotechReality Business Intelligence Desk
Cipher Pharmaceuticals Q3 2026 Results: Epuris Sales Rise 15%, Natroba Gains 14% as Net Income Hits $10.9M
Business Healthcare & Pharmaceuticals News

Cipher Pharmaceuticals Q3 2026 Results: Epuris Sales Rise 15%, Natroba Gains 14% as Net Income Hits $10.9M

14 November 202614 November 2026
Editor's Desk
Advertisement
BiotechReality JobFinder

  • Quality Systems Engineer – Boston Scientific, Dubai
    13 November 2026
  • Global Clinical Supply Business Support Coordinator – Pfizer, Makati
    9 November 2026
  • Senior Product Analyst – Novartis, India
    25 October 2026
  • Rare Disease Medical Science Liaison (MSL) – Amgen, Japan
    20 October 2026
  • Clinical Project Management Director – IQVIA
    16 October 2026

BiotechReality Shots Weekly Newsletter

Processing…
Success! You're on the list.
Whoops! There was an error and we couldn't process your subscription. Please reload the page and try again.
SciRealityPress BiotechReality

A SciRealityPress Associate

Contents in the website is licensed under CC BY-NC 4.0

Disclaimer: The content on this website is not meant to provide medical or any other professional advice. Understand and use the information, double check if necessary. All trademarked names mentioned in the contents belongs to their respective owners. Stock exchange data providing by Stockdio

SciRealityPress © 2026
  • About
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • Disclaimer
  • Platform Status
  • Market Analysis
  • Healthcare & Pharmaceuticals
    • Business
    • Pharmacology
  • Clinical Trials
    • Regulatory Approval
  • Biotechnology
    • Molecular Biology
    • Genomics
    • Immunology
    • Microbiology
      • Virology
    • Diagnostic Tests
  • Science
    • Microbiology
    • Research
    • General Biology
  • Technology
    • Artificial Intelligence
  • News
    • Research
  • Newsletters
  • linkedin
  • facebook
  • instagram
  • twitter